The adeno-associated viral vector market is anticipated to grow at a CAGR of more than 10% by 2035, claims Roots Analysis Given their low immunogenicity, diversified targets and ability to offer higher biosafety, the adeno-associated viral vectors are actively being evaluated for the development of various therapies for the treatment of chronic diseases and infections. London Roots Analysis has announced the addition of “Adeno Viral Vector Market, 2022-2035” report to its list of offerings. Owing to their unique biology, simple structure and lack of disease correlation, the adeno-associated viral vectors have garnered significant interest within the medical community. In fact, various adeno-associated viral vector-based therapies have been developed for the treatment of multiple indications, including retinitis pigmentosa, cystic fibrosis and Duchenne muscular dystrophy. As a result, the demand for such vectors have increased tremendously, thereby creating lucrative opportunities for the players engaged in the adeno-associated viral vector market. Among various gene delivery vectors available, adeno-associated viral (AAV) vectors have emerged as one of the most efficient viral vectors. Till now, the USFDA has approved two adeno-associated viral vectors based drugs, LUXTURNA® and ZOLGENSMA®. Considering the prevalent trends and projected opportunity associated with the overall adeno-associated viral vectors / AAV vector domain, we believe that the market is anticipated to witness substantial growth in the foreseen future. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/adeno-associated-viral-vector-market/request-sample.html Key Market Insights More than 550 adeno-associated viral vector-based therapies have been / are being evaluated across different stages of development for the treatment of various disorders Close to 20% of the pipeline candidates are under clinical evaluation; majority (26%) of these candidates are being developed for the treatment of neurological disorders, followed by those being evaluated for the treatment of ophthalmic disorders (21%). More than 155 clinical trials have been registered for the evaluation of adeno-associated viral vector-based therapies, worldwide The clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 20%, since 2010. Of the total number of trials registered, close to 25% have already been completed, while 46% of the studies are actively recruiting participants. More than 50 start-ups have emerged in the last 10 years in the adeno-associated viral vector domain Close to 60% of the start-ups have been established in North America. Among these, more than 95% of the firms are based in the US. This is followed by Europe, accounting for more than 30% of the start-ups focused on adeno-associated viral vectors. North America is anticipated to capture larger share of the adeno-associated viral vector market by 2035 The market will be primarily driven by the manufacturers developing therapies for the treatment of oncological disorders (20%). In addition, by 2035, majority market share of the adeno-associated viral vector-based therapies is anticipated to be dominated by commercial scale of operation (46%), followed by preclinical (40%) and clinical (14%). For additional details please visit https://www.rootsanalysis.com/reports/adeno-associated-viral-vector-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/